{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+Level+3&page=24",
    "query": {
      "intervention": "Dose Level 3",
      "page": 24
    },
    "page_size": 10
  },
  "pagination": {
    "page": 24,
    "page_size": 10,
    "total_count": 17839,
    "total_pages": 1784,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+Level+3&page=25&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+Level+3&page=23&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-18T06:31:07.640Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00803972",
      "title": "Dose-Ranging, Pharmacokinetic (PK), Glucodynamic (GD), Safety and Tolerability Study of Subcutaneously (SC) Administered Humulin R and Humalog With or Without rHuPH20",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "rHuPH20",
          "type": "DRUG"
        },
        {
          "name": "Insulin Human Injection",
          "type": "DRUG"
        },
        {
          "name": "Insulin Lispro Injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Halozyme Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 42,
      "start_date": "2008-11",
      "completion_date": "2009-08-28",
      "has_results": false,
      "last_update_posted_date": "2018-08-15",
      "last_synced_at": "2026-11-18T06:31:07.640Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00803972"
    },
    {
      "nct_id": "NCT02264639",
      "title": "A Phase I Study to Assess the Safety of Pegcetacoplan (APL-2) as an Add-On to Standard of Care in Subjects With PNH",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Paroxysmal Nocturnal Hemoglobinuria (PNH)"
      ],
      "interventions": [
        {
          "name": "Pegcetacoplan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Apellis Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2015-02-23",
      "completion_date": "2018-10-22",
      "has_results": true,
      "last_update_posted_date": "2021-01-08",
      "last_synced_at": "2026-11-18T06:31:07.640Z",
      "location_count": 7,
      "location_summary": "Los Angeles, California • Miami Lakes, Florida • Louisville, Kentucky + 4 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Miami Lakes",
          "state": "Florida"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02264639"
    },
    {
      "nct_id": "NCT00176475",
      "title": "Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Leukemia",
        "Lymphoma",
        "Multiple Myeloma and Plasma Cell Neoplasm"
      ],
      "interventions": [
        {
          "name": "rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "therapeutic allogeneic lymphocytes",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "University of Medicine and Dentistry of New Jersey",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2005-01",
      "completion_date": "2008-02",
      "has_results": false,
      "last_update_posted_date": "2013-09-17",
      "last_synced_at": "2026-11-18T06:31:07.640Z",
      "location_count": 1,
      "location_summary": "New Brunswick, New Jersey",
      "locations": [
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00176475"
    },
    {
      "nct_id": "NCT04020575",
      "title": "Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "huMNC2-CAR44 CAR T cells or huMNC2-CAR22 CAR T cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "huMNC2-CAR44 CAR T cells or huMNC2-CAR22 CAR T cells @ RP2D",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Minerva Biotechnologies Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 69,
      "start_date": "2020-01-15",
      "completion_date": "2035-01-15",
      "has_results": false,
      "last_update_posted_date": "2023-06-18",
      "last_synced_at": "2026-11-18T06:31:07.640Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04020575"
    },
    {
      "nct_id": "NCT00375557",
      "title": "Safety and Efficacy of Divalproex and Quetiapine in Elderly Alzheimer's Dementia Patients",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Alzheimer's Disease",
        "Dementia",
        "Behavioral Symptoms"
      ],
      "interventions": [
        {
          "name": "Divalproex ER",
          "type": "DRUG"
        },
        {
          "name": "Quetiapine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Cincinnati",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "55 Years to 85 Years"
      },
      "enrollment_count": 0,
      "start_date": "2006-10",
      "completion_date": "2007-09",
      "has_results": false,
      "last_update_posted_date": "2015-05-27",
      "last_synced_at": "2026-11-18T06:31:07.640Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00375557"
    },
    {
      "nct_id": "NCT02644967",
      "title": "A Phase 2 Study to Assess the Safety and Efficacy of IMO-2125 With 8 mg Ipilimumab in Patients With Metastatic Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Melanoma"
      ],
      "interventions": [
        {
          "name": "IMO-2125",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Idera Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 53,
      "start_date": "2015-12",
      "completion_date": "2021-05",
      "has_results": true,
      "last_update_posted_date": "2022-08-03",
      "last_synced_at": "2026-11-18T06:31:07.640Z",
      "location_count": 10,
      "location_summary": "Tucson, Arizona • Tampa, Florida • Iowa City, Iowa + 7 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Westwood",
          "state": "Kansas"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02644967"
    },
    {
      "nct_id": "NCT02825836",
      "title": "Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL Subjects",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Relapsed/Refractory B Cell Malignancies",
        "Mantle Cell Lymphoma and Diffuse Large B Cell Lymphoma",
        "Chronic Lymphocytic Leukemia",
        "Small Lymphocytic Lymphoma",
        "Treatment-Naive B Cell Malignancies"
      ],
      "interventions": [
        {
          "name": "TL-895",
          "type": "DRUG"
        },
        {
          "name": "Navtemadlin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Telios Pharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 130,
      "start_date": "2016-08-26",
      "completion_date": "2025-12-01",
      "has_results": false,
      "last_update_posted_date": "2023-07-13",
      "last_synced_at": "2026-11-18T06:31:07.640Z",
      "location_count": 2,
      "location_summary": "Columbus, Ohio • Germantown, Tennessee",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Germantown",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02825836"
    },
    {
      "nct_id": "NCT02461771",
      "title": "Assessment of Safety, Tolerability and Pharmacokinetics of Intravitreal Pegcetacoplan (APL-2) for Patients With Wet AMD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neovascular Age-Related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Pegcetacoplan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Apellis Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 13,
      "start_date": "2015-01-28",
      "completion_date": "2016-03-08",
      "has_results": true,
      "last_update_posted_date": "2020-10-06",
      "last_synced_at": "2026-11-18T06:31:07.640Z",
      "location_count": 3,
      "location_summary": "Beverly Hills, California • Miami, Florida • Portsmouth, New Hampshire",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Portsmouth",
          "state": "New Hampshire"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02461771"
    },
    {
      "nct_id": "NCT02092181",
      "title": "A Pilot Study of Mirabegron and Behavioral Modification Including Pelvic Floor Exercise for Overactive Bladder in Parkinson's Disease (MAESTRO)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Parkinsons Disease"
      ],
      "interventions": [
        {
          "name": "Mirabegron",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Daniel Burdick, MD",
      "sponsor_class": "INDIV",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "30 Years to 85 Years"
      },
      "enrollment_count": 30,
      "start_date": "2014-03",
      "completion_date": "2018-07-01",
      "has_results": true,
      "last_update_posted_date": "2021-08-16",
      "last_synced_at": "2026-11-18T06:31:07.640Z",
      "location_count": 1,
      "location_summary": "Kirkland, Washington",
      "locations": [
        {
          "city": "Kirkland",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02092181"
    },
    {
      "nct_id": "NCT05877430",
      "title": "Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "NSCLC",
        "HNSCC",
        "Melanoma",
        "Metastatic Cancer",
        "Advanced Solid Tumor",
        "Advanced Cancer"
      ],
      "interventions": [
        {
          "name": "CJRB-101",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "CJ Bioscience, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 160,
      "start_date": "2023-09-11",
      "completion_date": "2027-10",
      "has_results": false,
      "last_update_posted_date": "2024-12-20",
      "last_synced_at": "2026-11-18T06:31:07.640Z",
      "location_count": 2,
      "location_summary": "Irvine, California • Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05877430"
    }
  ]
}